ONODERA GT Pharma

ONODERA GT Pharma is a Japanese biotechnology company specializing in the development of innovative gene therapies for intractable neurological diseases. As a member of the ONODERA Group, the company leverages advanced Adeno-Associated Virus (AAV) vector technology to target conditions such as Amyotrophic Lateral Sclerosis (ALS), Parkinson's disease, and Alzheimer's disease. Their lead program, OGT-001, is focused on treating ALS by delivering therapeutic genes directly to the central nervous system. The company aims to bridge the gap between academic research and clinical application to provide life-changing treatments for patients with neurodegenerative disorders. By collaborating with leading researchers like Dr. Shin-ichi Muramatsu, ONODERA GT Pharma is positioned at the forefront of gene therapy innovation in Japan.